**Name of Journal: *World Journal of Gastroenterology***

**Manuscript NO: 47330**

**Manuscript Type: REVIEW**

**Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified**

BrunoG *et al*.Proton pump inhibitors and gut microbiota

Giovanni Bruno, Piera Zaccari, Giulia Rocco, Giulia Scalese, Cristina Panetta, Barbara Porowska, Stefano Pontone, Carola Severi

**Giovanni Bruno, Piera Zaccari, Giulia Rocco, Giulia Scalese, Carola Severi,** Department of Internal Medicine and Medical Specialties, Gastroenterology Unit, Sapienza University of Rome, Rome 00161, Italy

**Barbara Porowska,** Department of Cardio-Thoracic, Vascular Surgery and Transplants, Sapienza University of Rome, Rome 00161, Italy

**Cristina Panetta, Stefano Pontone,** Department of Surgical Sciences, Sapienza University of Rome, Rome 00161, Italy

**ORCID number:** Giovanni Bruno (0000-0002-7348-2018); Piera Zaccari (0000-0002-4041-5601); Giulia Rocco (0000-0002-2853-5627); Giulia Scalese (0000-0001-9755-9334); Cristina Panetta (0000-0001-6308-5396); Barbara Porowska (0000-0002-5399-5051); Stefano Pontone (0000-0001-7148-3220); Carola Severi (0000-0001-9249-1318).

**Author contributions:** Bruno G, Zaccari P and Rocco G performed the literature search and wrote the manuscript; Porowska B critically revised the manuscript; Scalese G and Panetta C designed and created the figures; Pontone S and Severi C provided scientific guidance and equally contributed to the manuscript as senior authors; all authors revised and approved the final version of this article.

**Conflict-of-interest statement:** No potential conflicts of interest to report.

**Open-Access:** This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Stefano Pontone, MD, PhD, Research Assistant Professor,** Department of Surgical Sciences, Sapienza University of Rome, V.le Regina Elena 324, Rome 00161, Italy. stefano.pontone@uniroma1.it

**Telephone:** +39-06-49975503

**Received:** March 12, 2019

**Peer-review started:** March 13, 2019

**First decision:** March 27, 2019

**Revised:** April 2, 2019

**Accepted:** April 19, 2019

**Article in press:** April 20, 2019

**Published online:** June 14, 2019

**Abstract**

Proton pump inhibitors (PPIs) are common medications within the practice of gastroenterology. These drugs, which act through the irreversible inhibition of the hydrogen/potassium pump (H+/K+-ATPase pump) in the gastric parietal cells, are used in the treatment of several acid-related disorders. PPIs are generally well tolerated but, through the long-term reduction of gastric acid secretion, can increase the risk of an imbalance in gut microbiota composition (*i.e*., dysbiosis). The gut microbiota is a complex ecosystem in which microbes coexist and interact with the human host. Indeed, the resident gut bacteria are needed for multiple vital functions, such as nutrient and drug metabolism, the production of energy, defense against pathogens, the modulation of the immune system and support of the integrity of the gut mucosal barrier. The bacteria are collected in communities that vary in density and composition within each segment of the gastrointestinal (GI) tract. Therefore, every change in the gut ecosystem has been connected to an increased susceptibility or exacerbation of various GI disorders. The aim of this review is to summarize the recently available data on PPI-related microbiota alterations in each segment of the GI tract and to analyze the possible involvement of PPIs in the pathogenesis of several specific GI diseases.

**Key words:**Proton pump inhibitors; Hypochloridria; Gut microbiota; Dysbiosis; Gastrointestinal tract; Cancer; *Helicobacter pylori*; Gastrointestinal infections

© **The Author(s) 2019**. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The gut microbiota plays a fundamental role in the maintenance of human health. However, several drugs, including proton pump inhibitors, can cause dysbiosis, which in turn is responsible for different extra-intestinal and intestinal diseases. An up-to-date review of the literature was conducted to identify changes in gut microbiota composition related to chronic proton pump inhibitor therapy and to highlight the possible pathogenic involvement of dysbiosis in gastrointestinal disorders.

Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. *World J Gastroenterol* 2019; 25(22): 2706-2719

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i22/2706.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i22.2706

**INTRODUCTION**

Proton pump inhibitors (PPIs) are acid-suppressive agents and are among the most widely used and over-used drugs in the world[1]. PPIs are the first-choice treatment for acid-related disorders such as bleeding, peptic ulcers, gastroesophageal reflux, erosive esophagitis (ERD) and certain dyspepsia subtypes[2-5]. The use of PPIs is generally well tolerated, although their long-term use exposes patients to an increased risk of developing extra-intestinal disorders[6-8], likely due to PPI-driven gastric hypochlorhydria, which can cause also significant changes in gut microbiota composition[9-11] (Figure 1). The gut microbiota has a key role in metabolic, nutritional, physiological, defensive and immunological processes in the human body, and its composition is closely connected to individuals’ health and the diseases they experience[12,13]. Changes in this microbial equilibrium that is, dysbiosis can promote and influence the course of many intestinal and extra-intestinal diseases[14-16]. The impact of PPIs on gut microbiota composition is currently a popular topic, and over the years, several interesting manuscripts have been published that expand the knowledge in this field[17-20].

The aim of the current review is to summarize the more recent evidence on the effect of PPIs on the gut microbiota, focusing on various areas within the gastrointestinal (GI) tract, and to discuss the possible role of the associated dysbiosis in the pathogenesis of several GI disorders. In doing so, this study seeks to better understand how PPIs could alter, via gut microbiota imbalance, human homeostasis.

**ORAL CAVITY**

Despite the continuous introduction of different bacteria from humans’ external environment, the oral microbiota remains less variable compared to other areas of the GI tract. It is primarily composed of Firmicutes and Bacteroidetes, with Actinobacteria, Proteobacteria and Fusobacteria also present[21]. In terms of genera, the most present are *Streptococcus, Neisseria, Prevotella, Gemella, Granulicatella* and *Veillonella*[22,23]. The oral microbiota helps to enrich and shape the bacterial communities of the gut through the continuous inflow of food and saliva[24-26]. It has been reported that inflammatory diseases such as gingivitis and periodontitis, which cause a shift in the composition of the oral microbial community, can promote the production of toxic and carcinogenic metabolites, cytolytic enzymes and oral pathogen-derived lipopolysaccharide (LPS) that are able to colonize extra-oral sites due to transient bacteremia[27-29]. The spread of such toxic compounds has been reported to contribute to the development of many GI diseases, including irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) and cancer[30-33].

Currently, little data has been presented about the relationship between PPI use and oral microbiota composition. One study showed that, in healthy volunteers, a four-week esomeprazole administration of PPI caused an increase of *Fusobacterium* and *Leptotrichia* in the periodontal pocket, associated with a decrease of *Neisseria* and *Veillonella* in saliva and a parallel increase of *Streptococcus* in fecal samples; this suggests that PPIs may cause both oral and gut microbiota alterations[34]. Based on these data, the oral cavity could represent a potential source of microbiota information related to oral and non-oral disorders; it could also be an important indicator of dysbiosis in other areas of the GI tract.

**ESOPHAGUS**

The esophagus has a distinct microbiota, with a relatively stable environmental bacterial composition; it does not simply contain a transient microbial population originating from swallowing (*i.e*., from the oral cavity) or reflux (*i.e*., from the stomach). The distal tract is mostly colonized by Firmicutes, followed by Bacteroidetes, Actinobacteria*,* Proteobacteria and Fusobacteria, with the most represented genera being *Streptococcus,* followed by *Prevotella* and *Veillonella*[35]. On the basis of the differences in genera proportion, two types of microbiota have been identified in the esophagus: Type I, present in healthy subjects, is characterized by a predominance of Gram-positive taxa (especially *Streptococcus*), whereas type II, associated with ERD and Barrett esophagus (BE), is constituted by a predominance of Gram-negative taxa, including *Veillonella, Prevotella, Haemophilus, Neisseria, Rothia, Granulicatella, Campylobacter, Porphyromonas, Fusobacterium* and *Actinomyces,* with a relative decrease in the abundance of *Streptococcus*[36,37]. It is likely that this switch in favor of Gram-negative bacteria could cause an LPS-mediated activation of innate immunity, inducing a dangerous cycle of dysbiosis-inflammation-dysbiosis and mucosal damage[38].

Since the early 1980s, a dysbiosis-mediated inflammatory response and the increased production of pro-carcinogenic bacterial compounds have been thought to contribute to carcinogenesis[39], a hypothesis recently re-confirmed and studied[40]. Both ERD and BE are considered precursor conditions to esophageal adenocarcinoma (EAC)[41]. In both these conditions, a significant enrichment of *Campylobacter* *concisus* has been reported[42,43]. This bacterium could have a role in EAC, promoting the metaplastic processes in the early stages of cancer through an increase in the interleukin (IL)-18 expression and downregulation of transforming growth factor beta 1, nuclear factor kappa B (NF-κB) and signal transducer and activator of transcription 3 signaling involved in the EAC cascade[42-44]. Moreover, the presence of *Fusobacterium nucleatum* (*F. nucleatum*)has been described in esophageal cancers and has been associated with a poor prognosis, suggesting its potential role as a prognostic biomarker[45]. Finally, esophageal samples of BE with high-grade dysplasia and EAC show a decreased microbiota diversity and a relative abundance of *Lactobacillales* that, through their capability to acidify the microenvironment and to produce harmful substances such as hydrogen peroxide, might contribute to the development of these diseases[46].

Currently, studies related to the effects of PPIs on the esophageal microbiota and their ability to reverse the microbial switch that occurs in ERD and BE are scarce. PPI treatment can alter esophageal microbiota, causing an increase in the abundance of Firmicutes and a decrease in the abundance of Bacteroidetes and Proteobacteria[47]. This evidence, obtained through both aspirates and biopsies, suggests that some bacterial families can colonize an esophagus exposed to lesser acidic refluxes, even if their role needs to be ascertained. A recent epidemiological study revealed that, in the absence of other risk factors, the long-term use of PPIs is associated with an increased risk of EAC[48]. The authors hypothesized that PPI therapy itself could predispose patients to EAC, likely through the colonization of non-gastric microbes capable of producing nitrosamines, which are known to possess carcinogenic potential for both EAC and esophageal squamous carcinoma. This concept stands in contrast with the actual guidelines that recommend PPI use in patients with non-dysplastic BE[49] because their long-term use significantly decreases the risk of the progression to high-grade dysplasia and EAC[50-52]. It has been hypothesized that the reduction of gastric acid reflux in the esophagus induced by PPIs avoids the death of acid-sensitive bacteria that have beneficial effects in the maintenance of a type I microbiota[53].

**STOMACH**

The gastric microbiota is composed mainly of Firmicutes, Bacteroidetes, Proteobacteria and Actinobacteria, with the most abundant genera being *Streptococcus*, followed by *Veillonella*, *Prevotella*, *Fusobacterium* and *Rothia*[54]. The impact of PPIs on gastric pH and the gastric microbiota has been the starting point for research in this field, but only recently have data demonstrated the importance of the consequences of long-term PPI use. PPIs have unfavorable effects on gastric functions and host defensive mechanisms, causing delayed gastric emptying, decreased gastric mucus viscosity, increased bacterial load and increased bacterial translocation[55-57]. *Streptococcaceae* are the most abundant family observed during PPI therapy, followed by *Prevotellaceae,* *Campylobacteraceae* and *Leptotrichiaceae*[58]*.* The primary abundance of *Streptococcaceae* was also demonstrated in dyspeptic patients during PPI treatment, suggesting that this ecological switch in favor of *Streptococcaceae* could be an independent indicator of gastric dysbiosis due to these drugs[59].

It is important to keep in mind that hypochlorhydria promotes a reduction in microbial diversity and the growth of microbes that have genotoxic potential, with an increase in the nitrate/nitrite reductase bacterial functions involved in cancer development[60]. Moreover, high gastric pH values can give rise to a different bacterial balance characterized by a significant increase in oral bacteria, such as *Peptostreptococcus stomatis, Streptococcus anginosus, Parvimonas micra, Slackia exigua* and *Dialister pneumosintes*. Through the induction of different metabolic pathways, such bacteria could have a role in gastric cancer (GC) progression[61]. Therefore, to better understand the power of promoting the survival and spread of potentially genotoxic bacteria in the stomach and other GI regions, it will be crucial to define the effects of PPIs in gastric microbiota composition. However, the role of PPIs in GC development is under debate, with some studies and meta-analyses reporting an increased risk of developing GC in long-term PPI users[62,63] up to 2.4 times greater, even after *Helicobacter pylori* (*H. pylori)* eradication, according to a recent study[64] and other meta-analyses not confirming such a risk[65,66].

Gastric dysbiosis occurs as a result of *H. pylori*-related gastritis. *H. pylori* pro-inflammatory activity affects the luminal microenvironment and modifies the gastric microbiota. During the infection, the gastric microbiota is predominantly constituted of Proteobacteria,followed byFirmicutes, Bacteroidetesand Actinobacteria[54]*.* It is noteworthy that, depending on the site of *H. pylori* colonization, the dysbiosis can be associated with either an increase or decrease in acid secretion, which further influences gastric microbiota composition. *H. pylori* infection can lead to antrum-predominant gastritis, in which the oxyntic mucosa is not inflamed but a gastrin-driven increase in acid output occurs, along with the possible development of duodenal ulcer[67,68]. In addition, when the infection does spread to the oxyntic mucosa, it causes pangastritis, which is associated with hypochloridria, and is responsible for the development of chronic atrophic gastritis, intestinal metaplasia and, finally, dysplasia and GC[69,70]. Several studies have shown that the bacterial migration from the antrum to gastric body and fundus occurs more frequently during long-term PPIs use[71]. Therefore, it is recommended to eradicate *H. pylori* infection in all patients who require long-term PPI therapy to stop the pro-inflammatory stimulus and still reduce the risk of GC[72,73].

**SMALL INTESTINE**

The density and composition of the bacterial population in the small intestinal tracts (*i.e*., the duodenum, jejunum and ileum) are influenced by several factors, including transit time, the presence of chemical factors, oxygen levels and the presence of antimicrobial substances that modulate bacterial growth[74]. Regarding the duodenal and jejunum, the predominant phyla are Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria and Fusobacteria. Facultative anaerobes such as *Streptococcus, Haemophilus, Escherichia, Actinomyces* and obligate anaerobes such as *Veillonella, Prevotella* and *Fusobacterium* are the most abundant genera[75-77]. Despite several sampling techniques having been used, the human ileal microbiota remains poorly characterized[78]. Previously, evidence based on biopsies collected by retrograde colonoscopy showed that the major phylogenetic groups are similar between the distal ileum and rectum[79,80]. In contrast, a recent study on samples collected surgically revealed profound differences between ileal and colonic microbiota, suggesting that the microbiota of the distal ileum appears to be constituted mainly by facultative anaerobic species within the *Bacilli* class (*e.g*., *Streptococcaceae, Lactobacillacae, Aerococcaceae,* and *Carnobacteriaceae*) and not by strict anaerobic species from the *Clostridia* class. However, it is likely that these results are not completely representative of normal ileal flora due to several influencing factors, such as the high age of the patients studied, comorbidity and antibiotic use[78].

Chronic treatment with PPIs strongly impacts small intestine microbiota and, in particular, causes small intestinal bacterial overgrowth (SIBO), likely due to the loss of the gastric acid defensive barrier[81-83]. SIBO is a condition defined by the presence of more than 105 bacteria per ml of upper gut aspirate and characterized mostly by weight loss, diarrhea, bloating and malabsorption[84]. In jejunal samples of SIBO patients, an overgrowth of microaerophilic microorganisms such as *Streptococcus*, *Staphylococcus*, *Escherichia*, and *Klebsiella* and anaerobic bacteria such as *Bacteroides*, *Lactobacillus*, *Veillonella* and *Clostridium* was found[85]. Likely, the increased production of toxic agents such as ammonia, D-lactate, endogenous bacterial peptidoglycans, serum endotoxin and bacterial compounds stimulates the secretion of proinflammatory cytokines, causing symptoms to develop and the malabsorption of fat and lipophilic vitamins by the deconjugation of bile acids to occur[86,87].

PPI-induced dysbiosis may represent a risk factor for hepatic encephalopathy (HE) and spontaneous bacterial peritonitis (SBP) in cirrhotic patients[88-90]. In such patients, the development of SIBO is prompted by intestinal dysmotility and the alteration of mucosal barrier integrity, facilitating the spread of pathogens and bacterial metabolism products, such as nitrogenous substances and toxins. This spread occurs through the circulatory and lymphatic systems and results in a plausibly increased risk of SBP, HE and more generally life-threatening infections[91,92].

It is noteworthy that some of the microbial changes caused by PPIs are the same as the alterations already present in patients with cirrhosis and especially in patients with decompensated cirrhosis including the relative increase of potentially pathogenic bacteria such as *Staphylococcaeae*, *Enterobacteriaceae* and *Enterococcaceae*[93]. This dysbiosis has also been shown to be related to the occurrence of HE and SBP, implying a poor prognosis and disease progression. For this reason, the use of minimally absorbed antibiotics, such as rifaximin, and prebiotics, such as lactulose, represents the cornerstone of treatment for HE[94]. Therefore, in patients with liver diseases, regardless of the severity of the underlying hepatopathy, PPIs may increase the risk of complications and should be administered only in the presence of a specific therapeutic indication.

PPIs have also been reported to exacerbate the mucosal damage caused by non-steroidal anti-inflammatory drugs (NSAIDs) in the distal portion of the small bowel to the ligament of Treitz[95,96], which stands in contrast to the protective effects of PPIs on NSAIDs-induced upper GI mucosal injury[97]. Even if the exact mechanism by which it occurs is not clear, bacterial imbalance can play an important role and, as such, has been investigated in a number of studies conducted in murine models (Figure 2). In rats, a PPI-driven significant reduction of Actinobacteria and *Bifidobacteria* spp. in the jejunum was shown to exacerbate NSAID-induced enteropathy[98]. Moreover, PPIs augmented the expression of bacteria with beta-glucuronidases activity, and this microbial imbalance could promote the spread of NSAIDs into enterohepatic circulation, increasing bile cytotoxicity and subsequently causing ulcerative lesions[99,100]. The role of dysbiosis in mucosal injuries was further supported by the beneficial effects of the co-administration of a *Bifidobacteria*-enriched commensal bacteria suspension, which was able to reduce mucosal damage[98]. Moreover, germ-free mice are less susceptible to intestinal lesions induced by NSAIDs and it has been documented that NSAID-induced enteropathy is transferable via microbiota[98,101,102]. Based on these observations, confirmation of the role of dysbiosis in humans is needed.

**COLON**

The colon harbors the largest number of microbes per unit volume of the whole GI tract[103]. On fecal and biopsy samples, the four predominant phyla are Firmicutes and Bacteroidetes*,* followed byActinobacteria and Proteobacteria[104,105], with a discrete inter-individual variability, especially regarding bacterial species and strains. The most represented bacterial clusters, called *enterotypes*, are constituted by a variation in the levels of one of these three genera: *Bacteroides* (enterotype 1), *Prevotella* (enterotype 2) and *Ruminococcus* (enterotype 3)[106,107]. PPIs by reducing gastric acid secretion can produce profound changes in the colonic microbiota, mainly characterized by a decrease in the abundance of commensal bacteria, which is associated with a reduction in microbial diversity and an increase of oral bacteria in the stool[108,109]. Therefore, it is reasonable to assume that PPI-driven dysbiosis significantly impacts host health.

PPIs can influence the onset of enteric infections, resulting in an increased risk of *Clostridium difficile* infection(CDI), as well as *Salmonella*, *Campylobacter* anddiarrheagenic *Escherichia coli* (*E. coli*)[110-113]. Even if not fully clarified, it has been hypothesized that, in CDI, a reduction in alpha diversity and a decrease in the abundance of bacteria of the *Ruminococcoceae* associated with an increase in the *Enterobacteriaceae, Enterococcoceae* and *Lactobacillaceae* families observed during long-term PPI treatment could facilitate the onset of infection[109]. This likely occurs because the increase of *Proteobacteria* members promotes the induction and maintenance of a pro-inflammatory environment[114,115].

It is likely that PPI use predisposes patients to the development of IBS[116]. As previously stated, the long-term PPI use facilitates the induction of enteric infection, and, through secondary changes in microbiota composition, these drugs may influence gut–brain axis functions, prompting IBS onset[117,118]. That dysbiosis plays a role in IBS, and especially the strong association between gut infection and IBS, has been supported by several studies[119,120]. Indeed, it has been found that 10%-30% of patients who develop post-infectious IBS following an infectious gastroenteritis can be considered to be in a post-inflammatory condition, exacerbated by acute stress[121-124]. Moreover, the role of gut microbiota composition in the pathogenesis of IBS is sustained by the success of certain probiotics in IBS symptom amelioration[125,126]. The IBS dysbiosis mostly consists of a reduction in alpha diversity and an imbalance between microbial groups, represented by a scarce amount *Bifidobacteria* and *Lactobacilli* members and an increase in potentially pathogenic *Enterobacteriaceae*, such as *E. coli*[127,128]; this is similar to what has been observed in patients who have undergone chronic PPI therapy[109].

Regarding IBDs, various observations have led researchers to postulate that chronic PPI administration may have a negative effect on such conditions[129,130]. At present, the data on microbial imbalance during IBD have not been not fully elucidated. Some studies have documented a reduced abundance of Firmicutes and Bacteroidetes, while others have reported an increase[131,132]. Overall, an increase in Proteobacteria has almost always been described[133,134]. It is thought that during IBD, a reduction in protective bacteria occurs in parallel with an increase in pro-inflammatory bacteria. Both in Crohn’s disease (CD) and ulcerative colitis (UC), higher concentrations of *E. coli* have been observed, and particularly of a variant called adherent-invasive *E. coli*, which is able to colonize the ileal mucosa and is responsible for the early inflammatory state[135,136]. Specifically, a reduction in anti-inflammatory bacteria, such as *Faecalibacterium prausnitzii*, *Bifidobacterium adolescentis*, and *Dialister invisus,* has been observed in CD sample analyses associated with unknown species of *Clostridium* (especially clusters IV and XIVa)[137]. In UC, a decrease in *Akkermansia muciniphila*, *Roseburia* and *Faecalibacterium prausnitzii,* along with an increase in *Fusobacterium* species, has been documented[138,139]. In the context of dysbiosis, PPIs may lead to short-term flare ups in the course of IBDs. This is likely because IBD patients are particularly susceptible to the development of bacterial superinfections, especially those caused by *Clostridium difficile*, *Campylobacter, Salmonella, Shigella* and *Entamoeba histolytica*, which represent harmful stimuli that can induce a relapse of the disease in a microenvironment that is already altered[140,141]. Moreover, the expansion of *Proteobacteria* could facilitate a mucosal immune response in genetically predisposed individuals, leading to the development and continuation of chronic intestinal inflammation[133, 142,143].

Finally, our review focused on colorectal cancer (CRC). Nowadays, it is well known that the only microorganism that has a primary and direct role in the development of GI tumors is *H. pylori*. However, the intricate and overall action that the imbalance of gut microbiota can play in conditioning the colon microenvironment and favoring oncogenesis is emerging, with great interest on the part of researchers[144-146]. As previously stated, PPI therapy facilitates the presence of oral bacteria in the stool[108,109]. In this context, the role of *F. nucleatum* should be carefully analyzed. *F. nucleatum* is a commensal anaerobic bacterium of the oral cavity associated with periodontal disorders, and it has been found in large quantities in CRC[147]. Its pro-inflammatory activity in the intestinal mucosa has been well described, and its presence could be related to patient outcome[148,149]. This microorganism has two adhesion proteins, FapA and FadA, the latter of which mediates the invasion of the bacterium into the intestinal epithelium. The consequence of this invasion is the promotion of NF-κB signaling and the expression of several cytokines, such as IL-6, IL-8, IL-10, IL-18 and TNF-α. The net result of these changes is the creation of a pro-inflammatory milieu for tumor growth, favored by the FapA-mediated suppression of T cells’ cytotoxic activity[147,150]. Therefore, studies have specified that identifying the presence of this bacterium in PPI users and especially those with concomitant oral disorders is a necessity.

Last, chronic hypergastrinemia, typically present during PPI use, can promote the growth of malignant colonic epithelial cells, facilitating the deleterious sequencing adenoma-carcinoma[151-153]. Nevertheless, it is fundamental to highlight that many studies over the years have not found a direct correlation between PPI use in clinical practice and an increased risk of CRC[154-156].

**CONCLUSIONS**

In an era in which gut microbiota science enjoys much attention[157,158], it seems crucial to define which types of drugs have an impact on gut microbiota composition. The evidence indicates that PPIs which are widely used in gastroenterology clinical practice likely through their acid-antisecretory effects, are able to modify the host microbiota in each segment of the GI tract and can contribute to dysbiosis development; this dysbiosis can, in turn, facilitate the onset of certain GI disorders. Moreover, the gastric hypochlorhydria caused by PPIs favors the survival and migration of oral bacteria in lower areas of the GI tract, with a possible establishment of a pro-inflammatory microenvironment. Further prospective studies are necessary to define how the microbial changes due to PPIs impact human health. Moreover, therapeutic strategies, such as probiotic supplementation, could be a useful approach to prevent dysbiosis during PPI treatment; however, the validity of this observation remains to be seen. Currently, the use of PPIs is recommended only when strictly necessary due to their possible ability to induce dysbiosis.

**REFERENCES**

1 **Scarpignato C**, Pelosini I, Di Mario F. Acid suppression therapy: Where do we go from here? *Dig Dis* 2006; **24**: 11-46 [PMID: 16699262 DOI: 10.1159/000091298]

2 **Bardou M**, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: Proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. *Aliment Pharmacol Ther* 2005; **21**: 677-686 [PMID: 15771753 DOI: 10.1111/j.1365-2036.2005.02391.x]

3 **DeVault KR**, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 2005; **100**: 190-200 [PMID: 15654800 DOI: 10.1111/j.1572-0241.2005.41217.x]

4 **Sharma VK**, Leontiadis GI, Howden CW. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. *Aliment Pharmacol Ther* 2001; **15**: 227-231 [PMID: 11148442 DOI: 10.1046/j.1365-2036.2001.00904.x]

5 **Suzuki H**, Okada S, Hibi T. Proton-pump inhibitors for the treatment of functional dyspepsia. *Therap Adv Gastroenterol* 2011; **4**: 219-226 [PMID: 21765866 DOI: 10.1177/1756283X11398735]

6 **Islam MM**, Poly TN, Walther BA, Dubey NK, Anggraini Ningrum DN, Shabbir SA, Jack Li YC. Adverse outcomes of long-term use of proton pump inhibitors: A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2018; **30**: 1395-1405 [PMID: 30028775 DOI: 10.1097/MEG.0000000000001198]

7 **de la Coba Ortiz C**, Argüelles Arias F, Martín de Argila de Prados C, Júdez Gutiérrez J, Linares Rodríguez A, Ortega Alonso A, Rodríguez de Santiago E, Rodríguez-Téllez M, Vera Mendoza MI, Aguilera Castro L, Álvarez Sánchez Á, Andrade Bellido RJ, Bao Pérez F, Castro Fernández M, Giganto Tomé F. Proton-pump inhibitors adverse effects: A review of the evidence and position statement by the Sociedad Española de Patología Digestiva. *Rev Esp Enferm Dig* 2016; **108**: 207-224 [PMID: 27034082 DOI: 10.17235/reed.2016.4232/2016]

8 **Eom CS**, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: A systematic review and meta-analysis. *CMAJ* 2011; **183**: 310-319 [PMID: 21173070 DOI: 10.1503/cmaj.092129]

9 **Tsuda A**, Suda W, Morita H, Takanashi K, Takagi A, Koga Y, Hattori M. Influence of Proton-Pump Inhibitors on the Luminal Microbiota in the Gastrointestinal Tract. *Clin Transl Gastroenterol* 2015; **6**: e89 [PMID: 26065717 DOI: 10.1038/ctg.2015.20]

10 **Freedberg DE**, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA. Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial. *Gastroenterology* 2015; **149**: 883-5.e9 [PMID: 26164495 DOI: 10.1053/j.gastro.2015.06.043]

11 **Takagi T**, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayama T, Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi H, Itoh Y. The influence of long-term use of proton pump inhibitors on the gut microbiota: An age-sex-matched case-control study. *J Clin Biochem Nutr* 2018; **62**: 100-105 [PMID: 29371761 DOI: 10.3164/jcbn.17-78]

12 **Jandhyala SM**, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. *World J Gastroenterol* 2015; **21**: 8787-8803 [PMID: 26269668 DOI: 10.3748/wjg.v21.i29.8787]

13 **Gerritsen J**, Smidt H, Rijkers GT, de Vos WM. Intestinal microbiota in human health and disease: The impact of probiotics. *Genes Nutr* 2011; **6**: 209-240 [PMID: 21617937 DOI: 10.1007/s12263-011-0229-7]

14 **Belizário JE**, Faintuch J, Garay-Malpartida M. Gut Microbiome Dysbiosis and Immunometabolism: New Frontiers for Treatment of Metabolic Diseases. *Mediators Inflamm* 2018; **2018**: 2037838 [PMID: 30622429 DOI: 10.1155/2018/2037838]

15 **DeGruttola AK**, Low D, Mizoguchi A, Mizoguchi E. Current Understanding of Dysbiosis in Disease in Human and Animal Models. *Inflamm Bowel Dis* 2016; **22**: 1137-1150 [PMID: 27070911 DOI: 10.1097/MIB.0000000000000750]

16 **Carding S**, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. *Microb Ecol Health Dis* 2015; **26**: 26191 [PMID: 25651997 DOI: 10.3402/mehd.v26.26191]

17 **Freedberg DE**, Lebwohl B, Abrams JA. The impact of proton pump inhibitors on the human gastrointestinal microbiome. *Clin Lab Med* 2014; **34**: 771-785 [PMID: 25439276 DOI: 10.1016/j.cll.2014.08.008]

18 **Singh A**, Cresci GA, Kirby DF. Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome. *Nutr Clin Pract* 2018; **33**: 614-624 [PMID: 30071147 DOI: 10.1002/ncp.10181]

19 **Minalyan A**, Gabrielyan L, Scott D, Jacobs J, Pisegna JR. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors. *Curr Gastroenterol Rep* 2017; **19**: 42 [PMID: 28733944 DOI: 10.1007/s11894-017-0577-6]

20 **Imhann F**, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C, Zhernakova A, Weersma RK. The influence of proton pump inhibitors and other commonly used medication on the gut microbiota. *Gut Microbes* 2017; **8**: 351-358 [PMID: 28118083 DOI: 10.1080/19490976.2017.1284732]

21 **Zaura E**, Nicu EA, Krom BP, Keijser BJ. Acquiring and maintaining a normal oral microbiome: Current perspective. *Front Cell Infect Microbiol* 2014; **4**: 85 [PMID: 25019064 DOI: 10.3389/fcimb.2014.00085]

22 **Aas JA**, Paster BJ, Stokes LN, Olsen I, Dewhirst FE. Defining the normal bacterial flora of the oral cavity. *J Clin Microbiol* 2005; **43**: 5721-5732 [PMID: 16272510 DOI: 10.1128/JCM.43.11.5721-5732.2005]

23 **Arweiler NB**, Netuschil L. The Oral Microbiota. *Adv Exp Med Biol* 2016; **902**: 45-60 [PMID: 27161350 DOI: 10.1007/978-3-319-31248-4\_4]

24 **Andersson AF**, Lindberg M, Jakobsson H, Bäckhed F, Nyrén P, Engstrand L. Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS One* 2008; **3**: e2836 [PMID: 18665274 DOI: 10.1371/journal.pone.0002836]

25 **Segata N**, Haake SK, Mannon P, Lemon KP, Waldron L, Gevers D, Huttenhower C, Izard J. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. *Genome Biol* 2012; **13**: R42 [PMID: 22698087 DOI: 10.1186/gb-2012-13-6-r42]

26 **Dewhirst FE**, Chen T, Izard J, Paster BJ, Tanner AC, Yu WH, Lakshmanan A, Wade WG. The human oral microbiome. *J Bacteriol* 2010; **192**: 5002-5017 [PMID: 20656903 DOI: 10.1128/JB.00542-10]

27 **Zhang Y**, Wang X, Li H, Ni C, Du Z, Yan F. Human oral microbiota and its modulation for oral health. *Biomed Pharmacother* 2018; **99**: 883-893 [PMID: 29710488 DOI: 10.1016/j.biopha.2018.01.146]

28 **Han YW**, Wang X. Mobile microbiome: Oral bacteria in extra-oral infections and inflammation. *J Dent Res* 2013; **92**: 485-491 [PMID: 23625375 DOI: 10.1177/0022034513487559]

29 **Li X**, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. *Clin Microbiol Rev* 2000; **13**: 547-558 [PMID: 11023956 DOI: 10.1128/CMR.13.4.547]

30 **Fourie NH**, Wang D, Abey SK, Sherwin LB, Joseph PV, Rahim-Williams B, Ferguson EG, Henderson WA. The microbiome of the oral mucosa in irritable bowel syndrome. *Gut Microbes* 2016; **7**: 286-301 [PMID: 26963804 DOI: 10.1080/19490976.2016.1162363]

31 **Lucas López R**, Grande Burgos MJ, Gálvez A, Pérez Pulido R. The human gastrointestinal tract and oral microbiota in inflammatory bowel disease: A state of the science review. *APMIS* 2017; **125**: 3-10 [PMID: 27704622 DOI: 10.1111/apm.12609]

32 **Ahn J**, Chen CY, Hayes RB. Oral microbiome and oral and gastrointestinal cancer risk. *Cancer Causes Control* 2012; **23**: 399-404 [PMID: 22271008 DOI: 10.1007/s10552-011-9892-7]

33 **Karpiński TM**. Role of Oral Microbiota in Cancer Development. *Microorganisms* 2019; **7**: pii: E20 [PMID: 30642137 DOI: 10.3390/microorganisms7010020]

34 **Mishiro T**, Oka K, Kuroki Y, Takahashi M, Tatsumi K, Saitoh T, Tobita H, Ishimura N, Sato S, Ishihara S, Sekine J, Wada K, Kinoshita Y. Oral microbiome alterations of healthy volunteers with proton pump inhibitor. *J Gastroenterol Hepatol* 2018; **33**: 1059-1066 [PMID: 29105152 DOI: 10.1111/jgh.14040]

35 **Pei Z**, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. Bacterial biota in the human distal esophagus. *Proc Natl Acad Sci U S A* 2004; **101**: 4250-4255 [PMID: 15016918 DOI: 10.1073/pnas.0306398101]

36 **Abrams JA**. The microbiome as a potential biomarker for oesophageal adenocarcinoma. *Lancet Gastroenterol Hepatol* 2017; **2**: 4-6 [PMID: 28404013 DOI: 10.1016/S2468-1253(16)30177-7]

37 **Yang L**, Francois F, Pei Z. Molecular pathways: Pathogenesis and clinical implications of microbiome alteration in esophagitis and Barrett esophagus. *Clin Cancer Res* 2012; **18**: 2138-2144 [PMID: 22344232 DOI: 10.1158/1078-0432.CCR-11-0934]

38 **Di Pilato V**, Freschi G, Ringressi MN, Pallecchi L, Rossolini GM, Bechi P. The esophageal microbiota in health and disease. *Ann N Y Acad Sci* 2016; **1381**: 21-33 [PMID: 27415419 DOI: 10.1111/nyas.13127]

39 **Lau WF**, Wong J, Lam KH, Ong GB. Oesophageal microbial flora in carcinoma of the oesophagus. *Aust N Z J Surg* 1981; **51**: 52-55 [PMID: 7013751 DOI: 10.1111/j.1445-2197.1981.tb05905.x]

40 **Baba Y**, Iwatsuki M, Yoshida N, Watanabe M, Baba H. Review of the gut microbiome and esophageal cancer: Pathogenesis and potential clinical implications. *Ann Gastroenterol Surg* 2017; **1**: 99-104 [PMID: 29863142 DOI: 10.1002/ags3.12014]

41 **Cook MB**, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, Gammon MD, Risch HA, Casson AG, Freedman ND, Chow WH, Wu AH, Bernstein L, Nyrén O, Pandeya N, Whiteman DC, Vaughan TL. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: A pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). *PLoS One* 2014; **9**: e103508 [PMID: 25075959 DOI: 10.1371/journal.pone.0103508]

42 **Macfarlane S**, Furrie E, Macfarlane GT, Dillon JF. Microbial colonization of the upper gastrointestinal tract in patients with Barrett's esophagus. *Clin Infect Dis* 2007; **45**: 29-38 [PMID: 17554697 DOI: 10.1086/518578]

43 **Blackett KL**, Siddhi SS, Cleary S, Steed H, Miller MH, Macfarlane S, Macfarlane GT, Dillon JF. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma: Association or causality? *Aliment Pharmacol Ther* 2013; **37**: 1084-1092 [PMID: 23600758 DOI: 10.1111/apt.12317]

44 **Kaakoush NO**, Castaño-Rodríguez N, Man SM, Mitchell HM. Is Campylobacter to esophageal adenocarcinoma as Helicobacter is to gastric adenocarcinoma? *Trends Microbiol* 2015; **23**: 455-462 [PMID: 25937501 DOI: 10.1016/j.tim.2015.03.009]

45 **Yamamura K**, Baba Y, Nakagawa S, Mima K, Miyake K, Nakamura K, Sawayama H, Kinoshita K, Ishimoto T, Iwatsuki M, Sakamoto Y, Yamashita Y, Yoshida N, Watanabe M, Baba H. Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis. *Clin Cancer Res* 2016; **22**: 5574-5581 [PMID: 27769987 DOI: 10.1158/1078-0432.CCR-16-1786]

46 **Elliott DRF**, Walker AW, O'Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic device to sample the oesophageal microbiota: A case-control study. *Lancet Gastroenterol Hepatol* 2017; **2**: 32-42 [PMID: 28404012 DOI: 10.1016/S2468-1253(16)30086-3]

47 **Amir I**, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett's oesophagus and further modified by proton pump inhibitors. *Environ Microbiol* 2014; **16**: 2905-2914 [PMID: 24112768 DOI: 10.1111/1462-2920.12285]

48 **Brusselaers N**, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. *Cancer Epidemiol* 2018; **53**: 172-177 [PMID: 29477057 DOI: 10.1016/j.canep.2018.02.004]

49 **Shaheen NJ**, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus. *Am J Gastroenterol* 2016; **111**: 30-50; quiz 51 [PMID: 26526079 DOI: 10.1038/ajg.2015.322]

50 **de Jonge PJ**, Steyerberg EW, Kuipers EJ, Honkoop P, Wolters LM, Kerkhof M, van Dekken H, Siersema PD. Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus. *Am J Gastroenterol* 2006; **101**: 1421-1429 [PMID: 16863542 DOI: 10.1111/j.1572-0241.2006.00626.x]

51 **Nguyen DM**, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. *Clin Gastroenterol Hepatol* 2009; **7**: 1299-1304 [PMID: 19523538 DOI: 10.1016/j.cgh.2009.06.001]

52 **Singh S**, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: A systematic review and meta-analysis. *Gut* 2014; **63**: 1229-1237 [PMID: 24221456 DOI: 10.1136/gutjnl-2013-305997]

53 **Neto AG**, Whitaker A, Pei Z. Microbiome and potential targets for chemoprevention of esophageal adenocarcinoma. *Semin Oncol* 2016; **43**: 86-96 [PMID: 26970127 DOI: 10.1053/j.seminoncol.2015.09.005]

54 **Bruno G**, Rocco G, Zaccari P, Porowska B, Mascellino MT, Severi C. Helicobacter pylori Infection and Gastric Dysbiosis: Can Probiotics Administration Be Useful to Treat This Condition? *Can J Infect Dis Med Microbiol* 2018; **2018**: 6237239 [PMID: 30275917 DOI: 10.1155/2018/6237239]

55 **Scarpignato C**, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. *BMC Med* 2016; **14**: 179 [PMID: 27825371 DOI: 10.1186/s12916-016-0718-z]

56 **Huang JQ**, Hunt RH. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician. *Best Pract Res Clin Gastroenterol* 2001; **15**: 355-370 [PMID: 11403532 DOI: 10.1053/bega.2001.0184]

57 **Wandall JH**. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation, and translocation of cytochrome b-245. *Gut* 1992; **33**: 617-621 [PMID: 1319381 DOI: 10.1136/gut.33.5.617]

58 **Parsons BN**, Ijaz UZ, D'Amore R, Burkitt MD, Eccles R, Lenzi L, Duckworth CA, Moore AR, Tiszlavicz L, Varro A, Hall N, Pritchard DM. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. *PLoS Pathog* 2017; **13**: e1006653 [PMID: 29095917 DOI: 10.1371/journal.ppat.1006653]

59 **Paroni Sterbini F**, Palladini A, Masucci L, Cannistraci CV, Pastorino R, Ianiro G, Bugli F, Martini C, Ricciardi W, Gasbarrini A, Sanguinetti M, Cammarota G, Posteraro B. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients. *Appl Environ Microbiol* 2016; **82**: 6633-6644 [PMID: 27590821 DOI: 10.1128/AEM.01437-16]

60 **Ferreira RM**, Pereira-Marques J, Pinto-Ribeiro I, Costa JL, Carneiro F, Machado JC, Figueiredo C. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. *Gut* 2018; **67**: 226-236 [PMID: 29102920 DOI: 10.1136/gutjnl-2017-314205]

61 **Coker OO**, Dai Z, Nie Y, Zhao G, Cao L, Nakatsu G, Wu WK, Wong SH, Chen Z, Sung JJY, Yu J. Mucosal microbiome dysbiosis in gastric carcinogenesis. *Gut* 2018; **67**: 1024-1032 [PMID: 28765474 DOI: 10.1136/gutjnl-2017-314281]

62 **Ahn JS**, Eom CS, Jeon CY, Park SM. Acid suppressive drugs and gastric cancer: A meta-analysis of observational studies. *World J Gastroenterol* 2013; **19**: 2560-2568 [PMID: 23674860 DOI: 10.3748/wjg.v19.i16.2560]

63 **Brusselaers N**, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: A nationwide population-based cohort study in Sweden. *BMJ Open* 2017; **7**: e017739 [PMID: 29084798 DOI: 10.1136/bmjopen-2017-017739]

64 **Cheung KS**, Chan EW, Wong AYS, Chen L, Wong ICK, Leung WK. Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: A population-based study. *Gut* 2018; **67**: 28-35 [PMID: 29089382 DOI: 10.1136/gutjnl-2017-314605]

65 **Song H**, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. *Cochrane Database Syst Rev* 2014; **(12)**: CD010623 [PMID: 25464111 DOI: [10.1002/14651858.CD010623.pub2](https://doi.org/10.1002/14651858.CD010623.pub2)]

66 **Eslami L**, Nasseri-Moghaddam S. Meta-analyses: Does long-term PPI use increase the risk of gastric premalignant lesions? *Arch Iran Med* 2013; **16**: 449-458 [PMID: 23906249]

67 **Kusters JG**, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. *Clin Microbiol Rev* 2006; **19**: 449-490 [PMID: 16847081 DOI: 10.1128/CMR.00054-05]

68 **Graham DY**. History of Helicobacter pylori, duodenal ulcer, gastric ulcer and gastric cancer. *World J Gastroenterol* 2014; **20**: 5191-5204 [PMID: 24833849 DOI: 10.3748/wjg.v20.i18.5191]

69 **Sung J**, Kim N, Lee J, Hwang YJ, Kim HW, Chung JW, Kim JW, Lee DH. Associations among Gastric Juice pH, Atrophic Gastritis, Intestinal Metaplasia and Helicobacter pylori Infection. *Gut Liver* 2018; **12**: 158-164 [PMID: 28918609 DOI: 10.5009/gnl17063]

70 **Correa P**. Helicobacter pylori and gastric carcinogenesis. *Am J Surg Pathol* 1995; **19 Suppl 1**: S37-S43 [PMID: 7762738 DOI: 10.1007/s00535-009-0014-1]

71 **Malfertheiner P**, Kandulski A, Venerito M. Proton-pump inhibitors: Understanding the complications and risks. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 697-710 [PMID: 28930292 DOI: 10.1038/nrgastro.2017.117]

72 **Malfertheiner P**, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. *Gut* 2017; **66**: 6-30 [PMID: 27707777 DOI: 10.1136/gutjnl-2016-312288]

73 **Ford AC**, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: Systematic review and meta-analysis of randomised controlled trials. *BMJ* 2014; **348**: g3174 [PMID: 24846275 DOI: 10.1136/bmj.g3174]

74 **Thursby E**, Juge N. Introduction to the human gut microbiota. *Biochem J* 2017; **474**: 1823-1836 [PMID: 28512250 DOI: 10.1042/BCJ20160510]

75 **Sundin OH**, Mendoza-Ladd A, Zeng M, Diaz-Arévalo D, Morales E, Fagan BM, Ordoñez J, Velez P, Antony N, McCallum RW. The human jejunum has an endogenous microbiota that differs from those in the oral cavity and colon. *BMC Microbiol* 2017; **17**: 160 [PMID: 28716079 DOI: 10.1186/s12866-017-1059-6]

76 **Wacklin P**, Kaukinen K, Tuovinen E, Collin P, Lindfors K, Partanen J, Mäki M, Mättö J. The duodenal microbiota composition of adult celiac disease patients is associated with the clinical manifestation of the disease. *Inflamm Bowel Dis* 2013; **19**: 934-941 [PMID: 23478804 DOI: 10.1097/MIB.0b013e31828029a9]

77 **Zhong L**, Shanahan ER, Raj A, Koloski NA, Fletcher L, Morrison M, Walker MM, Talley NJ, Holtmann G. Dyspepsia and the microbiome: Time to focus on the small intestine. *Gut* 2017; **66**: 1168-1169 [PMID: 27489239 DOI: 10.1136/gutjnl-2016-312574]

78 **Villmones HC**, Haug ES, Ulvestad E, Grude N, Stenstad T, Halland A, Kommedal Ø. Species Level Description of the Human Ileal Bacterial Microbiota. *Sci Rep* 2018; **8**: 4736 [PMID: 29549283 DOI: 10.1038/s41598-018-23198-5]

79 **Wang M**, Ahrné S, Jeppsson B, Molin G. Comparison of bacterial diversity along the human intestinal tract by direct cloning and sequencing of 16S rRNA genes. *FEMS Microbiol Ecol* 2005; **54**: 219-231 [PMID: 16332321 DOI: 10.1016/j.femsec.2005.03.012]

80 **Dave M**, Johnson LA, Walk ST, Young VB, Stidham RW, Chaudhary MN, Funnell J, Higgins PD. A randomised trial of sheathed versus standard forceps for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum. *Gut* 2011; **60**: 1043-1049 [PMID: 21317176 DOI: 10.1136/gut.2010.224337]

81 **Fujimori S**. What are the effects of proton pump inhibitors on the small intestine? *World J Gastroenterol* 2015; **21**: 6817-6819 [PMID: 26078557 DOI: 10.3748/wjg.v21.i22.6817]

82 **Spiegel BM**, Chey WD, Chang L. Bacterial overgrowth and irritable bowel syndrome: Unifying hypothesis or a spurious consequence of proton pump inhibitors? *Am J Gastroenterol* 2008; **103**: 2972-2976 [PMID: 19086951 DOI: 10.1111/j.1572-0241.2008.01992.x]

83 **Lo WK**, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: A meta-analysis. *Clin Gastroenterol Hepatol* 2013; **11**: 483-490 [PMID: 23270866 DOI: 10.1016/j.cgh.2012.12.011]

84 **Liang S**, Xu L, Zhang D, Wu Z. Effect of probiotics on small intestinal bacterial overgrowth in patients with gastric and colorectal cancer. *Turk J Gastroenterol* 2016; **27**: 227-232 [PMID: 27210778 DOI: 10.5152/tjg.2016.15375]

85 **Bouhnik Y**, Alain S, Attar A, Flourié B, Raskine L, Sanson-Le Pors MJ, Rambaud JC. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. *Scand J Gastroenterol.* 2008; **43** Suppl 9: 1030-7 [PMID: 10235214 DOI: 10.1111/j.1572-0241.1999.01016.x]

86 **Bures J**, Cyrany J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. *World J Gastroenterol* 2010; **16**: 2978-2990 [PMID: 20572300 DOI: 10.3748/wjg.v16.i24.2978]

87 **Fan X**, Sellin JH. Review article: Small intestinal bacterial overgrowth, bile acid malabsorption and gluten intolerance as possible causes of chronic watery diarrhoea. *Aliment Pharmacol Ther* 2009; **29**: 1069-1077 [PMID: 19222407 DOI: 10.1111/j.1365-2036.2009.03970.x]

88 **Nardelli S**, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. *Hepatology* 2018 [PMID: 30289992 DOI: 10.1002/hep.30304]

89 **Zhu J**, Qi X, Yu H, Yoshida EM, Mendez-Sanchez N, Zhang X, Wang R, Deng H, Li J, Han D, Guo X. Association of proton pump inhibitors with the risk of hepatic encephalopathy during hospitalization for liver cirrhosis. *United European Gastroenterol J* 2018; **6**: 1179-1187 [PMID: 30288280 DOI: 10.1177/2050640618773564]

90 **Dam G**, Vilstrup H, Watson H, Jepsen P. Proton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascites. *Hepatology* 2016; **64**: 1265-1272 [PMID: 27474889 DOI: 10.1002/hep.28737]

91 **Sturgeon JP**, Shawcross DL. Recent insights into the pathogenesis of hepatic encephalopathy and treatments. *Expert Rev Gastroenterol Hepatol* 2014; **8**: 83-100 [PMID: 24236755 DOI: 10.1586/17474124.2014.858598]

92 **Gupta A**, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J Hepatol* 2010; **53**: 849-855 [PMID: 20675008 DOI: 10.1016/j.jhep.2010.05.017]

93 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. *J Hepatol* 2014; **60**: 940-947 [PMID: 24374295 DOI: 10.1016/j.jhep.2013.12.019]

94 **Vilstrup H**, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology* 2014; **60**: 715-735 [PMID: 25042402 DOI: 10.1002/hep.27210]

95 **Marlicz W**, Loniewski I, Grimes DS, Quigley EM. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: Contrasting interactions in the stomach and small intestine. *Mayo Clin Proc* 2014; **89**: 1699-1709 [PMID: 25440891 DOI: 10.1016/j.mayocp.2014.07.015]

96 **Gwee KA**, Goh V, Lima G, Setia S. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: Risks versus benefits. *J Pain Res* 2018; **11**: 361-374 [PMID: 29491719 DOI: 10.2147/JPR.S156938]

97 **Scheiman JM**. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. *Arthritis Res Ther* 2013; **15 Suppl 3**: S5 [PMID: 24267413 DOI: 10.1186/ar4177]

98 **Wallace JL**, Syer S, Denou E, de Palma G, Vong L, McKnight W, Jury J, Bolla M, Bercik P, Collins SM, Verdu E, Ongini E. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. *Gastroenterology* 2011; **141**: 1314-1322, 1322.e1-1322.e5 [PMID: 21745447 DOI: 10.1053/j.gastro.2011.06.075]

99 **Blackler RW**, Motta JP, Manko A, Workentine M, Bercik P, Surette MG, Wallace JL. Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. *Br J Pharmacol* 2015; **172**: 992-1004 [PMID: 25297699 DOI: 10.1111/bph.12961]

100 **Syer SD**, Blackler RW, Martin R, de Palma G, Rossi L, Verdu E, Bercik P, Surette MG, Aucouturier A, Langella P, Wallace JL. NSAID enteropathy and bacteria: A complicated relationship. *J Gastroenterol* 2015; **50**: 387-393 [PMID: 25572030 DOI: 10.1007/s00535-014-1032-1]

101 **Uejima M**, Kinouchi T, Kataoka K, Hiraoka I, Ohnishi Y. Role of intestinal bacteria in ileal ulcer formation in rats treated with a nonsteroidal antiinflammatory drug. *Microbiol Immunol* 1996; **40**: 553-560 [PMID: 8887349 DOI: 10.1111/j.1348-0421.1996.tb01108.x]

102 **Robert A**, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. *Prostaglandins* 1977; **14**: 333-341 [PMID: 331401 DOI: 10.1016/0090-6980(77)90178-2]

103 **Sender R**, Fuchs S, Milo R. Revised Estimates for the Number of Human and Bacteria Cells in the Body. *PLoS Biol* 2016; **14**: e1002533 [PMID: 27541692 DOI: 10.1371/journal.pbio.1002533]

104 **Khanna S**, Tosh PK. A clinician's primer on the role of the microbiome in human health and disease. *Mayo Clin Proc* 2014; **89**: 107-114 [PMID: 24388028 DOI: 10.1016/j.mayocp.2013.10.011]

105 **Watt E**, Gemmell MR, Berry S, Glaire M, Farquharson F, Louis P, Murray GI, El-Omar E, Hold GL. Extending colonic mucosal microbiome analysis-assessment of colonic lavage as a proxy for endoscopic colonic biopsies. *Microbiome* 2016; **4**: 61 [PMID: 27884202 DOI: 10.1186/s40168-016-0207-9]

106 **Arumugam M**, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. Enterotypes of the human gut microbiome. *Nature* 2011; **473**: 174-180 [PMID: 21508958 DOI: 10.1038/nature09944]

107 **Shanahan F**. The colonic microbiota and colonic disease. *Curr Gastroenterol Rep* 2012; **14**: 446-452 [PMID: 22941733 DOI: 10.1007/s11894-012-0281-5]

108 **Jackson MA**, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter D, Ley RE, Bell JT, Spector TD, Steves CJ. Proton pump inhibitors alter the composition of the gut microbiota. *Gut* 2016; **65**: 749-756 [PMID: 26719299 DOI: 10.1136/gutjnl-2015-310861]

109 **Imhann F**, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA, Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK, Zhernakova A. Proton pump inhibitors affect the gut microbiome. *Gut* 2016; **65**: 740-748 [PMID: 26657899 DOI: 10.1136/gutjnl-2015-310376]

110 **Janarthanan S**, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: A meta-analysis. *Am J Gastroenterol* 2012; **107**: 1001-1010 [PMID: 22710578 DOI: 10.1038/ajg.2012.179]

111 **Trifan A**, Stanciu C, Girleanu I, Stoica OC, Singeap AM, Maxim R, Chiriac SA, Ciobica A, Boiculese L. Proton pump inhibitors therapy and risk of Clostridium difficile infection: Systematic review and meta-analysis. *World J Gastroenterol* 2017; **23**: 6500-6515 [PMID: 29085200 DOI: 10.3748/wjg.v23.i35.6500]

112 **Leonard J**, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007; **102**: 2047-56; quiz 2057 [PMID: 17509031 DOI: 10.1111/j.1572-0241.2007.01275.x]

113 **Bavishi C**, Dupont HL. Systematic review: The use of proton pump inhibitors and increased susceptibility to enteric infection. *Aliment Pharmacol Ther* 2011; **34**: 1269-1281 [PMID: 21999643 DOI: 10.1111/j.1365-2036.2011.04874.x]

114 **Rizzatti G**, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A. Proteobacteria: A Common Factor in Human Diseases. *Biomed Res Int* 2017; **2017**: 9351507 [PMID: 29230419 DOI: 10.1155/2017/9351507]

115 **Hakansson A**, Molin G. Gut microbiota and inflammation. *Nutrients* 2011; **3**: 637-682 [PMID: 22254115 DOI: 10.3390/nu3060637]

116 **Schmulson MJ**, Frati-Munari AC. Bowel symptoms in patients that receive proton pump inhibitors. Results of a multicenter survey in Mexico. *Rev Gastroenterol Mex* 2019; **84**: 44-51 [PMID: 29678362 DOI: 10.1016/j.rgmx.2018.02.008]

117 **Distrutti E**, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. *World J Gastroenterol* 2016; **22**: 2219-2241 [PMID: 26900286 DOI: 10.3748/wjg.v22.i7.2219]

118 **Carabotti M**, Scirocco A, Maselli MA, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. *Ann Gastroenterol* 2015; **28**: 203-209 [PMID: 25830558]

119 **Thabane M**, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. *Aliment Pharmacol Ther* 2007; **26**: 535-544 [PMID: 17661757 DOI: 10.1111/j.1365-2036.2007.03399.x]

120 **Marshall JK**, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM; Walkerton Health Study Investigators. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. *Gastroenterology* 2006; **131**: 445-50; quiz 660 [PMID: 16890598 DOI: 10.1053/j.gastro.2006.05.053]

121 **DuPont AW**. Postinfectious irritable bowel syndrome. *Clin Infect Dis* 2008; **46**: 594-599 [PMID: 18205536 DOI: 10.1086/526774]

122 **Kanazawa M**, Fukudo S. Relationship between infectious gastroenteritis and irritable bowel syndrome. *Clin J Gastroenterol* 2014; **7**: 14-18 [PMID: 26183503 DOI: 10.1007/s12328-013-0444-4]

123 **Thompson JR**. Is irritable bowel syndrome an infectious disease? *World J Gastroenterol* 2016; **22**: 1331-1334 [PMID: 26819502 DOI: 10.3748/wjg.v22.i4.1331]

124 **Kiank C**, Taché Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and post-infectious irritable bowel syndrome: Role of corticotropin-releasing factor receptors. *Brain Behav Immun* 2010; **24**: 41-48 [PMID: 19698778 DOI: 10.1016/j.bbi.2009.08.006]

125 **Moayyedi P**, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: A systematic review. *Gut* 2010; **59**: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]

126 **Aragon G**, Graham DB, Borum M, Doman DB. Probiotic therapy for irritable bowel syndrome. *Gastroenterol Hepatol (N Y)* 2010; **6**: 39-44 [PMID: 20567539]

127 **Si JM**, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. *World J Gastroenterol* 2004; **10**: 1802-1805 [PMID: 15188510 DOI: 10.3748/wjg.v10.i12.1802]

128 **El-Salhy M**. Recent developments in the pathophysiology of irritable bowel syndrome. *World J Gastroenterol* 2015; **21**: 7621-7636 [PMID: 26167065 DOI: 10.3748/wjg.v21.i25.7621]

129 **Shah R**, Richardson P, Yu H, Kramer J, Hou JK. Gastric Acid Suppression Is Associated with an Increased Risk of Adverse Outcomes in Inflammatory Bowel Disease. *Digestion* 2017; **95**: 188-193 [PMID: 28288458 DOI: 10.1159/000455008]

130 **Juillerat P**, Schneeweiss S, Cook EF, Ananthakrishnan AN, Mogun H, Korzenik JR. Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease. *Aliment Pharmacol Ther* 2012; **36**: 239-247 [PMID: 22670722 DOI: 10.1111/j.1365-2036.2012.05173.x]

131 **Ahmed I**, Roy BC, Khan SA, Septer S, Umar S. Microbiome, Metabolome and Inflammatory Bowel Disease. *Microorganisms* 2016; **4**: pii: E20 [PMID: 27681914 DOI: 10.3390/microorganisms4020020]

132 **Marchesi JR**, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, Thomas LV, Zoetendal EG, Hart A. The gut microbiota and host health: A new clinical frontier. *Gut* 2016; **65**: 330-339 [PMID: 26338727 DOI: 10.1136/gutjnl-2015-309990]

133 **Mukhopadhya I**, Hansen R, El-Omar EM, Hold GL. IBD-what role do Proteobacteria play? *Nat Rev Gastroenterol Hepatol* 2012; **9**: 219-230 [PMID: 22349170 DOI: 10.1038/nrgastro.2012.14]

134 **Matsuoka K**, Kanai T. The gut microbiota and inflammatory bowel disease. *Semin Immunopathol* 2015; **37**: 47-55 [PMID: 25420450 DOI: 10.1007/s00281-014-0454-4]

135 **Darfeuille-Michaud A**, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. *Gastroenterology* 2004; **127**: 412-421 [PMID: 15300573 DOI: 10.1053/j.gastro.2004.04.061]

136 **Sokol H**, Lepage P, Seksik P, Doré J, Marteau P. Temperature gradient gel electrophoresis of fecal 16S rRNA reveals active Escherichia coli in the microbiota of patients with ulcerative colitis. *J Clin Microbiol* 2006; **44**: 3172-3177 [PMID: 16954244 DOI: 10.1128/JCM.02600-05]

137 **Joossens M**, Huys G, Cnockaert M, De Preter V, Verbeke K, Rutgeerts P, Vandamme P, Vermeire S. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* 2011; **60**: 631-637 [PMID: 21209126 DOI: 10.1136/gut.2010.223263]

138 **Shen ZH**, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, Tan B, Wang XY. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. *World J Gastroenterol* 2018; **24**: 5-14 [PMID: 29358877 DOI: 10.3748/wjg.v24.i1.5]

139 **Machiels K**, Joossens M, Sabino J, De Preter V, Arijs I, Eeckhaut V, Ballet V, Claes K, Van Immerseel F, Verbeke K, Ferrante M, Verhaegen J, Rutgeerts P, Vermeire S. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. *Gut* 2014; **63**: 1275-1283 [PMID: 24021287 DOI: 10.1136/gutjnl-2013-304833]

140 **Mylonaki M**, Langmead L, Pantes A, Johnson F, Rampton DS. Enteric infection in relapse of inflammatory bowel disease: Importance of microbiological examination of stool. *Eur J Gastroenterol Hepatol* 2004; **16**: 775-778 [PMID: 15256979 DOI: 10.1097/01.meg.0000131040.38607.09]

141 **Singh S**, Graff LA, Bernstein CN. Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? *Am J Gastroenterol* 2009; **104**: 1298-313; quiz 1314 [PMID: 19337242 DOI: 10.1038/ajg.2009.15]

142 **Sartor RB**. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. *Am J Gastroenterol* 1997; **92**: 5S-11S [PMID: 9395346 DOI: 10.1046/j.1365-2036.1997.00255.x]

143 **Cho JH**. The genetics and immunopathogenesis of inflammatory bowel disease. *Nat Rev Immunol* 2008; **8**: 458-466 [PMID: 18500230 DOI: 10.1038/nri2340]

144 **Jobin C**. Colorectal cancer: Looking for answers in the microbiota. *Cancer Discov* 2013; **3**: 384-387 [PMID: 23580283 DOI: 10.1158/2159-8290.CD-13-0042]

145 **Ahn J**, Sinha R, Pei Z, Dominianni C, Wu J, Shi J, Goedert JJ, Hayes RB, Yang L. Human gut microbiome and risk for colorectal cancer. *J Natl Cancer Inst* 2013; **105**: 1907-1911 [PMID: 24316595 DOI: 10.1093/jnci/djt300]

146 **Raskov H**, Burcharth J, Pommergaard HC. Linking Gut Microbiota to Colorectal Cancer. *J Cancer* 2017; **8**: 3378-3395 [PMID: 29151921 DOI: 10.7150/jca.20497]

147 **Shang FM**, Liu HL. Fusobacterium nucleatum and colorectal cancer: A review. *World J Gastrointest Oncol* 2018; **10**: 71-81 [PMID: 29564037 DOI: 10.4251/wjgo.v10.i3.71]

148 **Flanagan L**, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. *Eur J Clin Microbiol Infect Dis* 2014; **33**: 1381-1390 [PMID: 24599709 DOI: 10.1007/s10096-014-2081-3]

149 **Tilg H**, Adolph TE, Gerner RR, Moschen AR. The Intestinal Microbiota in Colorectal Cancer. *Cancer Cell* 2018; **33**: 954-964 [PMID: 29657127 DOI: 10.1016/j.ccell.2018.03.004]

150 **Gao R**, Gao Z, Huang L, Qin H. Gut microbiota and colorectal cancer. *Eur J Clin Microbiol Infect Dis* 2017; **36**: 757-769 [PMID: 28063002 DOI: 10.1007/s10096-016-2881-8]

151 **Joshi SN**, Gardner JD. Gastrin and colon cancer: A unifying hypothesis. *Dig Dis* 1996; **14**: 334-344 [PMID: 9030465 DOI: 10.1159/000171567]

152 **Thorburn CM**, Friedman GD, Dickinson CJ, Vogelman JH, Orentreich N, Parsonnet J. Gastrin and colorectal cancer: A prospective study. *Gastroenterology* 1998; **115**: 275-280 [PMID: 9679032 DOI: 10.1016/S0016-5085(98)70193-3]

153 **Georgopoulos SD**, Polymeros D, Triantafyllou K, Spiliadi C, Mentis A, Karamanolis DG, Ladas SD. Hypergastrinemia is associated with increased risk of distal colon adenomas. *Digestion* 2006; **74**: 42-46 [PMID: 17068397 DOI: 10.1159/000096593]

154 **Yang YX**, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. *Gastroenterology* 2007; **133**: 748-754 [PMID: 17678926 DOI: 10.1053/j.gastro.2007.06.022]

155 **van Soest EM**, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. *Am J Gastroenterol* 2008; **103**: 966-973 [PMID: 18070237 DOI: 10.1111/j.1572-0241.2007.01665.x]

156 **Robertson DJ**, Larsson H, Friis S, Pedersen L, Baron JA, Sørensen HT. Proton pump inhibitor use and risk of colorectal cancer: A population-based, case-control study. *Gastroenterology* 2007; **133**: 755-760 [PMID: 17678921 DOI: 10.1053/j.gastro.2007.06.014]


157 **Guarner F**. Decade in review-gut microbiota: The gut microbiota era marches on. *Nat Rev Gastroenterol Hepatol* 2014; **11**: 647-649 [PMID: 25201043 DOI: 10.1038/nrgastro.2014.156]

158 **O’Grady J**, O'Connor EM, Shanahan F. Review article: Dietary fibre in the era of microbiome science. *Aliment Pharmacol Ther* 2019; **49**: 506-515 [PMID: 30746776 DOI: 10.1111/apt.15129]


**P-Reviewer:** Bang CS, Dinç T, Filik L, Li Y, Ulaşoğlu C **S-Editor:** Yan JP

**L-Editor:** A **E-Editor:** Zhang YL

**Specialty type:** Gastroenterology and hepatology   
**Country of origin:** Italy  
**Peer-review report classification**  
**Grade A (Excellent):** A   
**Grade B (Very good):** B, B  
**Grade C (Good):** C, C  
**Grade D (Fair):** 0 **Grade E (Poor):** 0

****

**Figure 1 Distribution of main bacterial families of human microbiota in physiological condition and during proton pump inhibitor treatment.** This figure shows the effect of proton pump inhibitor (PPI) treatment on the composition of gut microbiota families. The left side of the figure shows the principal bacterial families under normal physiological conditions; the right side of the figure shows the increase (**↑**) and decrease (↓) in bacterial families present in the gut microbiota during PPI treatment. PPI: Proton pump inhibitor.

****

**Figure 2 Proton pump inhibitors promote non-steroidal anti-inflammatory drug-induced enteropathy via microbiota.** Murine modelsdemonstrate that proton pump inhibitor (PPI) treatment, in addition to non-steroidal anti-inflammatory drugs (NSAIDs) therapy, brings about an exacerbation of mucosal damage in the small intestine. PPIs cause a bacterial imbalance, such as the reduction (↓) of *Actinobacteria* and *Bifidobacteria* spp., which is responsible for the mucosal damage. Specifically, PPIs increase the expression of bacteria with beta-glucuronidases activity and the consequent spreading of NSAIDs into enterohepatic circulation; ultimately, bile cytotoxicity then causes ulcerative intestinal lesions. The co-administration of *Bifidobacteria*-enriched suspension restores the gut microbiota and reduces mucosal damage. Germ-free mice are less susceptible to NSAIDs’ harmful effects and they develop NSAID-induced enteropathy through microbiota transfer. PPI: Proton pump inhibitor; NSAID: Non-steroidal anti-inflammatory drugs.